StockData
Evolus, Inc. logo

Evolus, Inc. (EOLS) stock

EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$6.69+0.06 (+0.90%)

Close on Nov 17, 2026Market cap $441.88MP/E –Yield –

Evolus operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Evolus's operating cash flow for the twelve months ending Jun 30, 2026 was -$15.38M. For fiscal 2025 it was -$42.27M. The highest annual figure on record is -$13.22M in fiscal 2017.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$42.27M–
FY2024Dec 31, 2024-$18.00M–
FY2023Dec 31, 2023-$34.01M–
FY2022Dec 31, 2022-$84.91M–
FY2021Dec 31, 2021-$33.39M–
FY2020Dec 31, 2020-$57.87M–
FY2019Dec 31, 2019-$93.38M–
FY2018Dec 31, 2018-$25.67M–
FY2017Dec 31, 2017-$13.22M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.59M–
Q1 FY2026Mar 31, 2026-$9.95M–
Q4 FY2025Dec 31, 2025$12.83M+166.8%
Q3 FY2025Sep 30, 2025-$14.67M–
Q2 FY2025Jun 30, 2025-$24.79M–
Q1 FY2025Mar 31, 2025-$15.63M–
Q4 FY2024Dec 31, 2024$4.81M+491.4%
Q3 FY2024Sep 30, 2024-$5.72M–
Q2 FY2024Jun 30, 2024-$6.47M–
Q1 FY2024Mar 31, 2024-$10.62M–
Q4 FY2023Dec 31, 2023$813.00K–
Q3 FY2023Sep 30, 2023-$924.00K–
Q2 FY2023Jun 30, 2023-$13.31M–
Q1 FY2023Mar 31, 2023-$20.59M–
Q4 FY2022Dec 31, 2022-$8.77M–
Q3 FY2022Sep 30, 2022-$17.05M–
Q2 FY2022Jun 30, 2022-$20.89M-229.6%
Q1 FY2022Mar 31, 2022-$38.20M–
Q4 FY2021Dec 31, 2021-$9.04M–
Q3 FY2021Sep 30, 2021-$32.13M–
Q2 FY2021Jun 30, 2021$16.12M–
Q1 FY2021Mar 31, 2021-$8.34M–
Q4 FY2020Dec 31, 2020-$2.27M–
Q3 FY2020Sep 30, 2020-$13.71M–
Q2 FY2020Jun 30, 2020-$13.95M–
Q1 FY2020Mar 31, 2020-$27.95M–
Q4 FY2019Dec 31, 2019-$15.92M–
Q3 FY2019Sep 30, 2019-$25.10M–
Q2 FY2019Jun 30, 2019-$33.16M–
Q1 FY2019Mar 31, 2019-$19.20M–
Q4 FY2018Dec 31, 2018-$12.01M–
Q3 FY2018Sep 30, 2018-$5.80M–
Q2 FY2018Jun 30, 2018-$5.66M–
Q1 FY2018Mar 31, 2018-$2.20M–
Q4 FY2017Dec 31, 2017-$1.00M–
Q3 FY2017Sep 30, 2017-$3.43M–
Q2 FY2017Jun 30, 2017-$3.21M–
Q1 FY2017Mar 31, 2017-$5.58M–

More Evolus figures

See a number that looks wrong?